Development of a New Antileishmanial Aziridine-2,3-Dicarboxylate-Based Inhibitor with High Selectivity for Parasite Cysteine Proteases.
Schad, Caroline
Development of a New Antileishmanial Aziridine-2,3-Dicarboxylate-Based Inhibitor with High Selectivity for Parasite Cysteine Proteases. [electronic resource] - Antimicrobial agents and chemotherapy Feb 2016 - 797-805 p. digital
Publication Type: Journal Article; Research Support, Non-U.S. Gov't
1098-6596
10.1128/AAC.00426-15 doi
Antiprotozoal Agents--chemistry
Aziridines--chemistry
Cathepsin B--antagonists & inhibitors
Cysteine Proteinase Inhibitors--chemistry
Leishmania major--drug effects
Leishmaniasis--drug therapy
Papain--antagonists & inhibitors
Th2 Cells--immunology
Development of a New Antileishmanial Aziridine-2,3-Dicarboxylate-Based Inhibitor with High Selectivity for Parasite Cysteine Proteases. [electronic resource] - Antimicrobial agents and chemotherapy Feb 2016 - 797-805 p. digital
Publication Type: Journal Article; Research Support, Non-U.S. Gov't
1098-6596
10.1128/AAC.00426-15 doi
Antiprotozoal Agents--chemistry
Aziridines--chemistry
Cathepsin B--antagonists & inhibitors
Cysteine Proteinase Inhibitors--chemistry
Leishmania major--drug effects
Leishmaniasis--drug therapy
Papain--antagonists & inhibitors
Th2 Cells--immunology